Dr. Hammers on the Future of Immunotherapy in RCC – OncLive
|
Dr. Hammers on the Future of Immunotherapy in RCC
OncLive Hans Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of immunotherapy for patients with renal cell carcinoma (RCC). For patients with recurrent metastatic disease, there are effective … |
